Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Raised to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Amphastar Pharmaceuticals (NASDAQ:AMPH) to a "strong-buy" rating, despite a broader analyst consensus of "Reduce" with an average price target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 consensus and revenues of $183.9 million, exceeding estimates of $179.92 million. Insider selling activity totaling 33,479 shares worth approximately $763,922 has been noted over the past 90 days.
AMPH5896384 Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for AMPH5896384 issued by Amphastar Pharmaceuticals, Inc., featuring a 2.0% coupon rate and maturing on March 15, 2029. It outlines key facts such as issue and maturity dates, face value, and minimum denomination, along with an upcoming semi-annual coupon payment schedule. The profile also touches on the company's business and bond redemption details, including an outstanding amount of $345.00 million USD.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Reduce" from Analysts
Eight analysts currently covering Amphastar Pharmaceuticals (NASDAQ:AMPH) have issued a consensus "Reduce" rating, with two recommending "sell" and six recommending "hold". Despite this, the company's shares opened at $26.68, above the average 12-month price target of $22.50, and recent quarterly results exceeded expectations with $0.91 EPS and $183.9 million in revenue. Over the past three months, insiders sold shares worth approximately $763,922, while institutional investors own 65.09% of the stock.
Bank of America Corp DE Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
Bank of America Corp DE recently acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the second quarter, purchasing 136,824 shares valued at approximately $2.76 million. Despite this new investment, analysts maintain a cautious outlook on AMPH with a consensus "Reduce" rating and an average price target of $22.50. The company reported strong Q2 earnings, surpassing revenue and EPS estimates, yet insider selling activity has been noted.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 5.7% - What's Next?
Amphastar Pharmaceuticals (NASDAQ:AMPH) shares rose 5.7% despite low trading volume, following better-than-expected quarterly earnings with $0.91 EPS against a $0.62 consensus and revenue of $183.9 million. Despite the positive earnings, analysts maintain a "Reduce" rating and a $22.50 price target, and insiders have recently sold over $760,000 worth of shares, suggesting a cautious outlook. The company specializes in injectable, inhaled, and intranasal biopharmaceutical products, including those for diabetes and respiratory conditions.
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells 4,139 Shares
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters sold 4,139 shares of the company's stock for a total of $103,475 under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Peters still directly owns 168,707 shares valued at approximately $4.2 million. The company recently reported strong quarterly earnings, significantly beating analyst estimates, although the consensus analyst rating remains "Reduce" with an average price target below the current trading price.
At $25 a share, Amphastar Pharmaceuticals (AMPH) CFO William Peters sold 4,139 shares.
Amphastar Pharmaceuticals' CFO, EVP & Treasurer William J. Peters, sold 4,139 shares of common stock at $25 per share on September 21, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 10, 2026, leaving him with 168,707 shares directly held. The insider sale, totaling approximately $103,000, was reported in a Form 4 filing with the SEC.
Amphastar (NASDAQ: AMPH) exec plans 4,139-share Rule 144 sale
An officer at Amphastar Pharmaceuticals, Inc. (AMPH), William J. Peters, has filed a Rule 144 notice to sell 4,139 shares of common stock, valued at $103,475.00, with a proposed sale date of September 21, 2026. These shares were acquired via RSU vesting on March 17, 2024. The filing also indicates a previous sale of 8,180 shares on August 7, 2026, generating $183,886.40.
Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 10,000 Shares of Stock
Amphastar Pharmaceuticals EVP Rong Zhou sold 10,000 shares of the company's stock for $239,400, reducing her direct holdings by 5.58% to 169,203 shares. Despite the sale, Amphastar reported strong quarterly earnings, beating EPS and revenue estimates. Analyst sentiment remains cautious, with a consensus "Reduce" rating and a target price of $22.50.
Squarepoint Ops LLC Has $1.59 Million Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH
Squarepoint Ops LLC significantly increased its stake in Amphastar Pharmaceuticals, Inc. by 178% in the second quarter, now holding 78,795 shares valued at $1.59 million. Despite this increase in institutional investment, analysts maintain a cautious "Reduce" rating for AMPH with a consensus price target of $22.50. The company recently surpassed quarterly earnings and revenue expectations, but corporate insiders have sold shares totaling $421,047 during the last quarter.
Legal & General Group Plc Makes New $1.58 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH
Legal & General Group Plc has made a new investment of $1.58 million in Amphastar Pharmaceuticals (NASDAQ:AMPH), acquiring 78,281 shares, which represents a 0.18% stake. This investment comes as Amphastar Pharmaceuticals reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. Despite positive earnings, analyst sentiment remains cautious with a consensus "Reduce" rating and insider selling activity observed over the past three months.
Bank of New York Mellon Corp Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
Bank of New York Mellon Corp recently acquired a new stake of 232,343 shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), valued at approximately $4.7 million. This investment gives Bank of New York Mellon Corp a 0.53% ownership stake in the company. Despite this institutional interest and strong Q2 earnings that beat analyst estimates, analyst sentiment remains cautious with an average "Reduce" rating for Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Recommendation of "Reduce" from Analysts
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received a "Reduce" consensus rating from analysts, with an average 12-month price target of $22.50, which is below its current share price of $23.18. Despite this, the company reported strong quarterly results, exceeding earnings and revenue expectations. Recent insider selling and increased institutional investor positions indicate mixed sentiment around the stock.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced that CFO Bill Peters and EVP of Regulatory Affairs and Clinical Operations Tony Marrs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 4:30 pm ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. Amphastar is a biopharmaceutical company specializing in developing, manufacturing, and commercializing complex generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that CFO Bill Peters and EVP Tony Marrs will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 4:30 p.m. ET. A webcast of the presentation will be available on the company's investor relations website for 30 days. The company is a biopharmaceutical firm specializing in generic and proprietary injectable, inhalation, and intranasal products, and also sells active pharmaceutical ingredients.
Bank of America Corp DE Acquires 46,149 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Bank of America Corp DE increased its stake in Amphastar Pharmaceuticals by 36% in the first quarter, purchasing an additional 46,149 shares and bringing its total holdings to 174,323 shares. This increased institutional ownership in the company to 65.09%, despite some insider selling. Amphastar Pharmaceuticals also reported strong quarterly earnings, surpassing analyst expectations with $0.91 EPS against an estimated $0.62.
(AMPH) and the Role of Price-Sensitive Allocations
This article provides an in-depth analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes an exceptional risk-reward short setup targeting 15.3% downside.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Passes Above 50-Day Moving Average - Should You Sell?
Amphastar Pharmaceuticals (NASDAQ:AMPH) stock recently surpassed its 50-day moving average, trading at $21.88 against a moving average of $20.16. Despite exceeding quarterly earnings and revenue expectations, analyst sentiment remains cautious with a consensus "Reduce" rating and a $22.50 target price, partly due to recent insider stock sales. Institutional investors have shown mixed activity, with some increasing and others initiating positions.
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar Pharmaceuticals (AMPH) is projected to report a year-over-year decline in earnings for the quarter ended June 2026, despite an expected increase in revenues. Analysts have recently become more bearish on the company's earnings prospects, leading to a negative Earnings ESP and a Zacks Rank of #5, making an earnings beat difficult to predict. Investors are advised to consider other factors beyond just an earnings beat or miss, and Supernus Pharmaceuticals (SUPN) is highlighted as a stronger earnings-beat candidate within the same industry.
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – NASDAQ:AMPH
The article focuses on the enterprise value to EBITDA forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data page from TradingView, providing an overview of the company's financial performance.
Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH
Denali Advisors LLC significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 41.1% in Q2, bringing its total holdings to 375,965 shares valued at $7.59 million. Despite Amphastar exceeding Q2 earnings expectations with $0.91 EPS against a $0.62 consensus, analyst sentiment remains cautious, with a "Reduce" rating and a $22.50 price target. This comes amidst insider share sales and institutional investors collectively owning a majority of the company's stock.
Barclays Issues Positive Forecast for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price
Barclays has increased its price target for Amphastar Pharmaceuticals (NASDAQ:AMPH) from $20 to $23, maintaining an "equal weight" rating and suggesting a 7.1% upside. Despite this, analyst sentiment remains cautious with a MarketBeat consensus rating of "Reduce" and an average target of $22.50. The company recently surpassed quarterly expectations, reporting $0.91 EPS against a $0.62 estimate and revenue of $183.9 million, exceeding the $179.9 million forecast.
Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) insider Floyd Petersen plans to sell 47,101 shares of common stock, valued at $989,121, through UBS Financial Services Inc. This sale is being executed under Rule 144, following an option exercise for cash on August 18, 2026, which is also the proposed sale date. The transaction represents a small fraction of the 44,092,000 shares outstanding.
Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating
Barclays has increased its price target for Amphastar Pharmaceuticals (AMPH) to $23 from $20, while maintaining an Equalweight rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, posting an adjusted EPS of $0.91, significantly exceeding the FactSet estimate of $0.62. Amphastar also reported Q2 revenue of $183.9M, surpassing the FactSet estimate of $179.9M.
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals
Amphastar Pharmaceuticals' Lead Independent Director, Richard Prins, recently sold US$162k worth of shares at an average price of US$20.30, reducing his holding by 27%. This was the largest insider sale in the past year for the company. While the sale occurred near the current stock price, which is not ideal, insiders still own 10% of Amphastar Pharmaceuticals, valued at about US$88 million.
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7,973 Shares
Richard Prins, a director at Amphastar Pharmaceuticals (AMPH), sold 7,973 shares of the company for approximately $161,852 on August 11, 2026. This sale contributes to a trend of insider selling at AMPH over the past year, with no insider buys recorded. Despite the insider selling, GuruFocus pegs the stock as "Significantly Undervalued" with a price-to-GF-Value ratio of 0.57.
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A
This article focuses on the enterprise value to EBITDA forward for Amphastar Pharmaceuticals, Inc. (MUN:29A) as listed on the Munich Stock Exchange. It indicates that the market is currently closed with no trades. The information is presented within the financial section of a trading platform.
Amphastar director Richard Prins disposes of shares valued at $161,851
Amphastar Pharmaceuticals director Richard K. Prins sold 7,973 shares of the company's common stock for $161,851. This transaction occurred on August 11, 2026, with shares priced at $20.3 each, leaving him with 29,625 shares. The sale follows the company's strong Q2 2026 revenue of $183.9 million, surpassing analyst estimates, driven by new product success despite a 25% year-to-date stock decline.
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock
Richard Prins, a director at Amphastar Pharmaceuticals (NASDAQ:AMPH), sold 7,973 shares of the company's stock for over $161,000, reducing his direct holdings by more than 21%. Despite the sale and a "Reduce" consensus rating from analysts, the company recently reported strong quarterly earnings, beating revenue and EPS estimates. Institutional investors hold a significant stake of 65.09% in Amphastar Pharmaceuticals.
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30
Richard K. Prins, a director at Amphastar Pharmaceuticals, Inc. (AMPH), sold 7,973 shares of the company's common stock at a price of $20.30 per share on August 11, 2026. This transaction, reported as an open market or private sale, leaves Prins with 29,625 shares of Amphastar common stock directly held. The Form 4 filing details this insider trading activity.
Amphastar CFO William Peters sells $183,886 in company stock
Amphastar Pharmaceuticals CFO William J. Peters sold 8,180 shares of company stock for $183,886 on August 7, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired 5,053 shares through employee stock option exercises for $99,998. Following these transactions, Peters beneficially owns 172,846 shares of Amphastar common stock.
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares
Amphastar Pharmaceuticals' CFO, William Peters, sold 8,180 shares of the company's stock for a total of $183,886.40, reducing his holdings by 4.52%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, though analyst sentiment for the stock remains cautious with a consensus "Reduce" rating.
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade
Amphastar Pharmaceuticals' CFO, William J. Peters, exercised 5,053 employee stock options at $19.79 per share and subsequently sold 8,180 shares of common stock at $22.48 per share on August 7, 2026. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 10, 2026. Following these transactions, Peters holds 172,846 shares of common stock and zero employee stock options from that grant.
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting
Amphastar Pharmaceuticals (AMPH) has filed a Rule 144 notice for the proposed sale of 7,973 shares of common stock, valued at $161,931.63, through UBS Financial Services Inc. The sale is scheduled for August 11, 2026, and is linked to multiple Restricted Stock Unit (RSU) vesting events that occurred between 2017 and 2025. The filing indicates 44,009,000 shares are outstanding.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts
Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Reduce" recommendation from eight brokerages, with two analysts rating it a "sell" and six a "hold." Despite this cautious sentiment and an average 12-month price target of $22.00, the company recently surpassed earnings expectations, reporting $0.91 EPS against a $0.62 consensus and $183.9 million in revenue. Institutional investors hold 65.09% of the company, whose shares opened at $20.31, falling within its 52-week range of $16.65 to $31.26.
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning
Amphastar Pharmaceuticals (AMPH) reported strong Q2 2026 revenue of $183.9M, a 5% year-over-year increase, significantly boosted by a $100M payment from a $175M BAQSIMI milestone. However, the company faces potential increased remediation costs and slowed batch releases due to an FDA warning letter issued to IMS.
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
This article provides an analysis of Amphastar Pharmaceuticals, Inc.'s recent financial performance, highlighting that the company exceeded consensus expectations. It is anticipated that analysts will update their estimates based on these strong results. The piece will likely delve into the specific financial metrics that contributed to the outperformance and discuss the potential implications for the company's future outlook and stock valuation.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler
Piper Sandler has reduced its price target for Amphastar Pharmaceuticals (AMPH) to $20.00 from $21.00, maintaining a "neutral" rating despite the company's recent earnings beat. While Amphastar exceeded analyst expectations with adjusted EPS of $0.91 and revenue of $183.9 million, overall analyst sentiment remains cautious, with a consensus "Reduce" rating and an average target price of $22.00. Other firms like Wells Fargo and Barclays also set their price targets at $20.00, indicating a conservative outlook on the stock's future performance.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating
Amphastar Pharmaceuticals (NASDAQ:AMPH) received an upgrade from Wall Street Zen to a "strong-buy" rating, despite a more cautious "reduce" consensus rating from other analysts. The company's recent quarterly results surpassed expectations with revenues of $183.9 million and adjusted EPS of $0.91, outperforming estimates. Institutional investors hold a significant portion of Amphastar's outstanding shares, while the stock currently trades below its 200-day moving average.
Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026)
This article reports on Amphastar Pharmaceuticals, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of securities, detailing the class of securities, the broker involved (UBS Financial Services, Inc.), the number of shares, aggregate market value, and the date of sale. It also specifies that the securities were acquired through RSU Vesting in March 2024.
Amphastar Pharmaceuticals, Inc. (AMPH) stock price, news, quote and history
This article provides a comprehensive overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, historical data, financial performance, and analyst ratings. It details the company's product portfolio, which includes various injectable, inhalation, and intranasal products, and lists key financial metrics and comparisons with similar companies.
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals reported a 5% year-over-year revenue increase in Q2 2026, reaching $183.9 million, driven by new product launches like ipratropium bromide inhalation. Despite a slight dip in net income, diluted EPS rose, and the company is addressing an FDA warning letter at its IMS subsidiary while continuing pipeline investments. Management maintains its corporate sales growth outlook for 2026, with an insulin biosimilar on track for 2027 commercialization.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), and adjusted non-GAAP net income was $40.8 million ($0.91 per share). The company highlighted overall revenue growth, expanded gross margins, successful new product launches like ipratropium bromide, and continued advancement in its generic and proprietary development pipelines, despite navigating pricing and competitive dynamics.
Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains
Amphastar Pharmaceuticals reported a 5% increase in Q2 2026 net revenues to $183.9 million, driven by growth in new products like Ipratropium bromide, despite declines in others such as BAQSIMI and Glucagon. The company achieved a gross margin expansion to 50.8%, although GAAP net income slightly decreased compared to the prior year. Amphastar also highlighted its robust pipeline, including several ANDA and biosimilar insulin candidates targeting markets exceeding $6.3 billion.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported better-than-expected Q2 CY2026 results, with revenue of $183.9 million exceeding analyst estimates by 2% and non-GAAP profit of $0.91 per share significantly beating consensus estimates. The company achieved 5.4% year-on-year revenue growth and highlighted successful key goals including overall revenue growth, expansion of gross margins, new product launches, and advancement in its development pipelines. Despite a decrease in operating margin this quarter, the company's long-term performance shows solid compounded annual growth rates for sales and EPS.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals, Inc. reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), while adjusted non-GAAP net income reached $40.8 million ($0.91 per share). The company highlighted continued execution of its diversification strategy, including new product launches and advancement of its generic and proprietary pipelines.
Pacer Advisors Inc. Buys 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 47.1% in the first quarter, purchasing 83,739 additional shares, bringing its total holdings to 261,483 shares valued at approximately $5.1 million. Despite this institutional interest, analyst sentiment remains cautious with a "Reduce" consensus rating and an average price target of $22, following Amphastar's recent quarterly earnings miss. The company's stock is trading near its 52-week low amidst these financial and analyst concerns.
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook Reveals 8.80% Upside Potential
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a biopharmaceutical company with a diverse product portfolio showing an 8.80% upside potential from its current stock price of $20.22, with an average target price of $22.00. Despite its strong free cash flow and return on equity, caution is advised due to an overbought RSI and cautious analyst sentiment with no buy ratings. The company's innovative product lineup and international expansion are key strengths for future growth.
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 12.7% in the first quarter, now owning over 2 million shares. Despite this institutional interest, Amphastar's recent quarterly earnings missed analyst expectations for both EPS and revenue, contributing to a "Reduce" consensus rating from analysts with an average price target of $22. The stock recently opened at $20.22, with 65.09% of its shares held by institutional investors and hedge funds.
Arrowstreet Capital Limited Partnership Has $6.37 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Arrowstreet Capital Limited Partnership reduced its stake in Amphastar Pharmaceuticals by 41.9% in Q1 2026, holding 325,291 shares valued at $6.37 million. Despite this, institutional ownership remains high at 65.09%, with other firms like Dimensional Fund Advisors and State Street increasing their positions. The stock currently has a "Reduce" consensus rating from analysts, with an average price target of $22, following recent quarterly earnings that missed estimates.
